Skip to main content

Table 3 The median methylation values for 7 CHD candidate genes showing significant differences between TOF cases and controls

From: Association of promoter methylation statuses of congenital heart defect candidate genes with Tetralogy of Fallot

Gene Gene bank accession Gene amplicon Control, median (IQR); N TOF, median (IQR); N P value Position
EGFR NM_201282 EGFR _M1 52.75(44.00-56.35);N = 6 60.50(56.10-68.08);N = 33 0.0042** CpGI
EVC2 NM_001166136 EVC2 _M1 29.63(18.84-32.25);N = 6 43.88(36.44-53.28);N = 32 0.0005*** CpGI
NFATC2 NM_001136021 NFATC2 _M2 21.80(17.50-25.53);N = 6 30.29(26.06-36.57);N = 41 0.0067** CpGI
NR2F2 NM_021005 NR2F2 62.50(54.35-68.30);N = 6 43.40(33.90-53.10);N = 41 0.0161* CpGI shore
TBX5 NM_080717 TBX5 _M1 42.04(32.97-54.69);N = 6 57.13(50.69-67.31);N = 37 0.0207* CpGI shore
CFC1B NM_001079530 CFC1B _M2 48.16(40.36-59.25);N = 6 63.50(53.57-80.60);N = 39 0.0178* TSS
GJA5 NM_005266 GJA5 32.83(29.00-36.08);N = 6 44.00(34.67-53.92);N = 36 0.0138* TSS
  1. *P < 0.05, **P < 0.01, ***P < 0.001 (Mann–Whitney test), IQR, Interquartile range.